Vice President Jennifer Che gave a talk at the Swiss Patent Attorney Associations and the Swiss Professional Attorney Association of Industrial Patent Attorneys (VESPA/VIPS) annual autumn seminar about key upcoming changes in China’s new Patent Law as well as other related new measures that are particularly relevant to pharma/biotech companies, including patent term extension, patent linkage, post-filing data, litigation reform, and patent eligibility in the biotech/pharma area.

我们的过去活动

Recommended Insights

How Far Can an Employer Reach to Own Employee-made “Service Inventions”?

2020年7月30日
2019 China’s Top 50 Representative IP Cases Shenzhen Weibang Technology Co. Ltd v. Li Jianyi & Shenzhen Yuancheng Intelligence Equipment Co. Ltd (2019最高法民申6342号) Each year in China there are hundreds of disputes over patent ownership.  A significant part of them are related to “Service Inventions”, which are defined in Article 6 of the Chinese Patent […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement

2022年12月2日
This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]

New Fee Standards Released for Chinese Patent Applications

2024年9月6日
Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE). Please find our summary below: PCT application fee deduction rules   Application fee & extra […]
Top crossarrow-right